The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal
Cannabis use disorder (CUD) commonly occurs and carries a notable economic and functional burden at both individual and societal levels. While there are no clearly efficacious medication treatments for CUD, 20 years of committed and high-quality research in the human laboratory and clinical settings...
Gespeichert in:
| Veröffentlicht in: | Neuropsychopharmacology (New York, N.Y.) N.Y.), 2018-01, Vol.43 (1), p.173-194 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 194 |
|---|---|
| container_issue | 1 |
| container_start_page | 173 |
| container_title | Neuropsychopharmacology (New York, N.Y.) |
| container_volume | 43 |
| creator | Brezing, Christina A Levin, Frances R |
| description | Cannabis use disorder (CUD) commonly occurs and carries a notable economic and functional burden at both individual and societal levels. While there are no clearly efficacious medication treatments for CUD, 20 years of committed and high-quality research in the human laboratory and clinical settings have resulted in medications with demonstrated effectiveness in the treatment of cannabis withdrawal, the ability to reduce cannabis use, and results that point to promising future work. The current state of pharmacology research for CUD highlights the need to consider particular characteristics of patients, such as gender, impulsivity, and severity of cannabis use, when selecting a medication in the off-label treatment of CUD or cannabis withdrawal. As a field, the body of work also exposes some areas in need of improvement in study design, selection of outcome measures, interpretation of results, and the overall process of evaluating candidate medications. Coming to a consensus as a field and addressing these gaps in future research will likely lend itself to further advances in improving the lives of patients with CUD. |
| doi_str_mv | 10.1038/npp.2017.212 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5719115</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1936267900</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-3522106db926ac3b98d2df416ecce7ec5eca029beae171da54dd6381240f41603</originalsourceid><addsrcrecordid>eNpdkU1v1DAQhi1ERZfCjTOyxIUDWTx24o8LElq-KlUCia3YmzWxnW6qJF7sBMS_x6uWqvQ0h3n0zjt6CHkBbA1M6LfT4bDmDNSaA39EVqBqVklR7x6TFdNGVCDE7pQ8zfmaMWiU1E_IKddaNUabFdlt94FulpTCNNPvM86Bxo5-22Ma0cUhXvUOB7pNAeexIJl2MdENThO2faaXOdAPfY7Jh0Rx8vRHP-99wt84PCMnHQ45PL-dZ-Ty08ft5kt18fXz-eb9ReVq4HMlGs6BSd8aLtGJ1mjPfVeDDM4FFVwTHDJu2oABFHhsau-l0MBrdqSYOCPvbnIPSzsG70rJhIM9pH7E9MdG7O3_m6nf26v4yzYKDEBTAl7fBqT4cwl5tmOfXRgGnEJcsgUjJJfKsOOtVw_Q67ikqbxXKMUkN1roQr25oVyKOafQ3ZUBZo_KbFFmj8psUVbwl_cfuIP_ORJ_AZ14kzY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1970629838</pqid></control><display><type>article</type><title>The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Brezing, Christina A ; Levin, Frances R</creator><creatorcontrib>Brezing, Christina A ; Levin, Frances R</creatorcontrib><description>Cannabis use disorder (CUD) commonly occurs and carries a notable economic and functional burden at both individual and societal levels. While there are no clearly efficacious medication treatments for CUD, 20 years of committed and high-quality research in the human laboratory and clinical settings have resulted in medications with demonstrated effectiveness in the treatment of cannabis withdrawal, the ability to reduce cannabis use, and results that point to promising future work. The current state of pharmacology research for CUD highlights the need to consider particular characteristics of patients, such as gender, impulsivity, and severity of cannabis use, when selecting a medication in the off-label treatment of CUD or cannabis withdrawal. As a field, the body of work also exposes some areas in need of improvement in study design, selection of outcome measures, interpretation of results, and the overall process of evaluating candidate medications. Coming to a consensus as a field and addressing these gaps in future research will likely lend itself to further advances in improving the lives of patients with CUD.</description><identifier>ISSN: 0893-133X</identifier><identifier>EISSN: 1740-634X</identifier><identifier>DOI: 10.1038/npp.2017.212</identifier><identifier>PMID: 28875989</identifier><language>eng</language><publisher>England: Nature Publishing Group</publisher><subject>Cannabis ; Cannabis - adverse effects ; Drug addiction ; Drug therapy ; Humans ; Impulsive behavior ; Marijuana ; Marijuana Abuse - drug therapy ; Neuropsychopharmacology Reviews ; Pharmacology ; Substance Withdrawal Syndrome - drug therapy</subject><ispartof>Neuropsychopharmacology (New York, N.Y.), 2018-01, Vol.43 (1), p.173-194</ispartof><rights>Copyright Nature Publishing Group Jan 2018</rights><rights>Copyright © 2018 American College of Neuropsychopharmacology 2018 American College of Neuropsychopharmacology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-3522106db926ac3b98d2df416ecce7ec5eca029beae171da54dd6381240f41603</citedby><cites>FETCH-LOGICAL-c412t-3522106db926ac3b98d2df416ecce7ec5eca029beae171da54dd6381240f41603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719115/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719115/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28875989$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brezing, Christina A</creatorcontrib><creatorcontrib>Levin, Frances R</creatorcontrib><title>The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal</title><title>Neuropsychopharmacology (New York, N.Y.)</title><addtitle>Neuropsychopharmacology</addtitle><description>Cannabis use disorder (CUD) commonly occurs and carries a notable economic and functional burden at both individual and societal levels. While there are no clearly efficacious medication treatments for CUD, 20 years of committed and high-quality research in the human laboratory and clinical settings have resulted in medications with demonstrated effectiveness in the treatment of cannabis withdrawal, the ability to reduce cannabis use, and results that point to promising future work. The current state of pharmacology research for CUD highlights the need to consider particular characteristics of patients, such as gender, impulsivity, and severity of cannabis use, when selecting a medication in the off-label treatment of CUD or cannabis withdrawal. As a field, the body of work also exposes some areas in need of improvement in study design, selection of outcome measures, interpretation of results, and the overall process of evaluating candidate medications. Coming to a consensus as a field and addressing these gaps in future research will likely lend itself to further advances in improving the lives of patients with CUD.</description><subject>Cannabis</subject><subject>Cannabis - adverse effects</subject><subject>Drug addiction</subject><subject>Drug therapy</subject><subject>Humans</subject><subject>Impulsive behavior</subject><subject>Marijuana</subject><subject>Marijuana Abuse - drug therapy</subject><subject>Neuropsychopharmacology Reviews</subject><subject>Pharmacology</subject><subject>Substance Withdrawal Syndrome - drug therapy</subject><issn>0893-133X</issn><issn>1740-634X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkU1v1DAQhi1ERZfCjTOyxIUDWTx24o8LElq-KlUCia3YmzWxnW6qJF7sBMS_x6uWqvQ0h3n0zjt6CHkBbA1M6LfT4bDmDNSaA39EVqBqVklR7x6TFdNGVCDE7pQ8zfmaMWiU1E_IKddaNUabFdlt94FulpTCNNPvM86Bxo5-22Ma0cUhXvUOB7pNAeexIJl2MdENThO2faaXOdAPfY7Jh0Rx8vRHP-99wt84PCMnHQ45PL-dZ-Ty08ft5kt18fXz-eb9ReVq4HMlGs6BSd8aLtGJ1mjPfVeDDM4FFVwTHDJu2oABFHhsau-l0MBrdqSYOCPvbnIPSzsG70rJhIM9pH7E9MdG7O3_m6nf26v4yzYKDEBTAl7fBqT4cwl5tmOfXRgGnEJcsgUjJJfKsOOtVw_Q67ikqbxXKMUkN1roQr25oVyKOafQ3ZUBZo_KbFFmj8psUVbwl_cfuIP_ORJ_AZ14kzY</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Brezing, Christina A</creator><creator>Levin, Frances R</creator><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180101</creationdate><title>The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal</title><author>Brezing, Christina A ; Levin, Frances R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-3522106db926ac3b98d2df416ecce7ec5eca029beae171da54dd6381240f41603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Cannabis</topic><topic>Cannabis - adverse effects</topic><topic>Drug addiction</topic><topic>Drug therapy</topic><topic>Humans</topic><topic>Impulsive behavior</topic><topic>Marijuana</topic><topic>Marijuana Abuse - drug therapy</topic><topic>Neuropsychopharmacology Reviews</topic><topic>Pharmacology</topic><topic>Substance Withdrawal Syndrome - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brezing, Christina A</creatorcontrib><creatorcontrib>Levin, Frances R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brezing, Christina A</au><au>Levin, Frances R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal</atitle><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle><addtitle>Neuropsychopharmacology</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>43</volume><issue>1</issue><spage>173</spage><epage>194</epage><pages>173-194</pages><issn>0893-133X</issn><eissn>1740-634X</eissn><abstract>Cannabis use disorder (CUD) commonly occurs and carries a notable economic and functional burden at both individual and societal levels. While there are no clearly efficacious medication treatments for CUD, 20 years of committed and high-quality research in the human laboratory and clinical settings have resulted in medications with demonstrated effectiveness in the treatment of cannabis withdrawal, the ability to reduce cannabis use, and results that point to promising future work. The current state of pharmacology research for CUD highlights the need to consider particular characteristics of patients, such as gender, impulsivity, and severity of cannabis use, when selecting a medication in the off-label treatment of CUD or cannabis withdrawal. As a field, the body of work also exposes some areas in need of improvement in study design, selection of outcome measures, interpretation of results, and the overall process of evaluating candidate medications. Coming to a consensus as a field and addressing these gaps in future research will likely lend itself to further advances in improving the lives of patients with CUD.</abstract><cop>England</cop><pub>Nature Publishing Group</pub><pmid>28875989</pmid><doi>10.1038/npp.2017.212</doi><tpages>22</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-133X |
| ispartof | Neuropsychopharmacology (New York, N.Y.), 2018-01, Vol.43 (1), p.173-194 |
| issn | 0893-133X 1740-634X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5719115 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Cannabis Cannabis - adverse effects Drug addiction Drug therapy Humans Impulsive behavior Marijuana Marijuana Abuse - drug therapy Neuropsychopharmacology Reviews Pharmacology Substance Withdrawal Syndrome - drug therapy |
| title | The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T19%3A52%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Current%20State%20of%20Pharmacological%20Treatments%20for%20Cannabis%20Use%20Disorder%20and%20Withdrawal&rft.jtitle=Neuropsychopharmacology%20(New%20York,%20N.Y.)&rft.au=Brezing,%20Christina%20A&rft.date=2018-01-01&rft.volume=43&rft.issue=1&rft.spage=173&rft.epage=194&rft.pages=173-194&rft.issn=0893-133X&rft.eissn=1740-634X&rft_id=info:doi/10.1038/npp.2017.212&rft_dat=%3Cproquest_pubme%3E1936267900%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1970629838&rft_id=info:pmid/28875989&rfr_iscdi=true |